Literature DB >> 7484015

Viridans streptococcal shock syndrome during bone marrow transplantation.

R Martino1, R Manteiga, I Sánchez, S Brunet, A Sureda, I Badell, B Argilés, M Subirá, R Bordes, A Domingo-Albós.   

Abstract

Of 320 patients receiving a marrow transplant at the Hospital de Sant Pau between 1986 and 1992, 12% developed viridans streptococcal bacteremia during severe neutropenia. Five of these patients (13%) developed a rapidly progressive fatal shock syndrome characterized by bilateral pulmonary infiltrates, acute respiratory failure (ARDS) and septic shock early in the transplantation course (6 or 7 days posttransplantation). All patients were transplanted for acute leukemia in remission, and 2 received an allogeneic and 3 an autologous transplant. Four of these subjects were younger than 15 years of age and all had received cyclophosphamide and total body irradiation as conditioning regimen for marrow transplantation. All 5 patients died, and postmortem examinations revealed diffuse pulmonary lesions characteristic of the ARDS. These observations contribute to defining the clinical and pathologic characteristics of this serious complication of intensive anticancer treatment.

Entities:  

Mesh:

Year:  1995        PMID: 7484015     DOI: 10.1159/000203976

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

1.  RegG, a CcpA homolog, participates in regulation of amylase-binding protein A gene (abpA) expression in Streptococcus gordonii.

Authors:  J D Rogers; F A Scannapieco
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences.

Authors:  M W Meyer; K Gong; M C Herzberg
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

3.  A case report of streptococcal toxic shock syndrome caused by Streptococcus mitis in a healthy adult.

Authors:  Xiang Chen; Ying Ying Gong; Li Zhang
Journal:  BMC Infect Dis       Date:  2021-02-06       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.